NexGen Franchising, LLC NexGenEsis Healthcare

The American healthcare system is failing millions of patients who suffer from chronic pain, degenerative joint conditions, and sports injuries but want to avoid a lifetime of opioid prescriptions or the risks of invasive surgery. This is the problem that NexGen Franchising, LLC NexGenEsis Healthcare was built to solve. Founded by Dr. Greg Picou, who serves as Chairman of the Board, the company operates at the intersection of regenerative medicine and primary care, delivering physician-supervised, non-surgical treatments that harness the body's own biology to accelerate healing. The leadership team includes Dr. Lawrence Bourgeois as Chief Executive Officer and Dr. Andrew McNall as Chief Operating Officer, a clinically credentialed trio that gives the brand unusual depth of medical authority relative to other healthcare franchise concepts. The company's headquarters have been cited across multiple locations, reflecting an organization in active geographic expansion across both Texas and Mississippi markets. NexGen Franchising, LLC NexGenEsis Healthcare began extending its model to franchisees beginning around 2020 to 2022, and by 2024 the system had reached 12 total units across the United States, comprising 10 company-owned locations and 2 franchised clinics, with more units awarded and in development. The brand's core service offerings span primary care, urgent care, telemedicine, platelet-rich plasma injections, alpha 2 macroglobulin therapy, and bone marrow aspirate procedures, positioning it as a comprehensive alternative and regenerative medicine platform rather than a single-modality clinic. For franchise investors evaluating healthcare opportunities, this is an early-stage system with a clinically grounded model operating in one of the highest-growth sectors in medicine. This analysis is produced independently by PeerSense and reflects research across public disclosures, franchise documents, and industry data sources — it is not marketing copy produced by the franchisor.

The alternative healthcare and regenerative medicine industry represented approximately $29 billion in annual U.S. market size as of 2023, and it is expanding at a pace that far outstrips the broader healthcare sector. The global regenerative medicine market is projected to grow at a 16% compound annual growth rate, with some analyses placing the expansion rate above 24% per year depending on how the category is defined. Within the United States specifically, the regenerative medicine segment is projected to reach $5 billion by 2030 and has been described by industry analysts as a $10 billion opportunity over a longer time horizon. These figures are being driven by several simultaneous demographic and cultural forces: an aging U.S. population that is increasingly mobility-conscious, a post-opioid crisis consumer base that is actively seeking non-addictive pain management alternatives, and a healthcare consumer cohort that places extraordinary value on minimally invasive interventions that preserve quality of life. The preference for avoiding surgery is not merely a trend but a structural shift — patients who have witnessed peers navigate lengthy post-surgical rehabilitation periods are demonstrating willingness to pay out of pocket for regenerative treatments that compress recovery timelines from months to weeks. Critically, the regenerative therapy market currently features limited direct competition in the franchise channel specifically, which means early entrants like NexGen Franchising, LLC NexGenEsis Healthcare operate in a relatively uncrowded landscape where brand establishment carries compounding long-term value. The services offered by NexGenEsis clinics — including treatments for weight loss, hair loss, and erectile dysfunction alongside the core regenerative and pain management protocols — also tap into the broader wellness economy, further expanding the total addressable patient base. The combination of secular demographic tailwinds, limited franchise channel competition, and a proven consumer willingness to self-pay for outcomes-driven healthcare creates an unusually attractive macro environment for this category of franchise investment.

The NexGen Franchising, LLC NexGenEsis Healthcare franchise cost structure reflects the medical nature of the business model, with an initial franchise fee set at $55,000. Veterans receive a 10% discount off the initial franchise fee, a meaningful incentive given the operational and leadership profile that prior military service tends to produce. The total estimated initial investment required to open a NexGenEsis Healthcare franchise ranges from approximately $168,250 to $361,495, a spread that is driven primarily by geography, lease market conditions, and the level of leasehold improvements required for any given clinical space. Breaking down that investment range reveals the capital allocation across a clinical build-out: the Initial Neuropathy Package runs $3,500; Modality Equipment Package costs between $6,500 and $10,000; the Regenerative Equipment Package ranges from $15,000 to $35,000; Furniture, Fixtures, and Supplies account for $10,000 to $20,000; Computer and POS Systems add $2,500 to $10,000; three months of Lease Payments range from $3,750 to $30,000; Leasehold Improvements span $10,000 to $75,000; Signage adds $2,500 to $5,000; Insurance runs $4,000 to $7,000; Professional Fees add $2,000 to $10,000; Training Costs range from $1,500 to $10,000; Medical Training adds up to $4,495; and three months of Additional Funds for working capital are estimated between $50,000 and $80,000. Licenses and permits add a further $500 to $1,500, and utility and security deposits contribute $1,500 to $5,000. The minimum liquid capital requirement has been cited at $100,000 by some sources and at $168,250 by others, suggesting franchisors expect candidates to be adequately capitalized before clinical operations begin. The ongoing royalty fee is 7.00% of gross sales, which is positioned at the higher end of the healthcare franchise category but is offset by the premium pricing power that regenerative medicine services command in a cash-pay environment. The brand fund contribution is 1% of gross sales, resulting in a combined ongoing fee rate of 8% before any local marketing expenditure. SBA loan eligibility is a financing pathway prospective franchisees should evaluate given the medical equipment intensity of the initial build-out, and veterans specifically should request documentation of the 10% fee discount in writing during the discovery process.

The daily operating model of a NexGenEsis Healthcare franchise is built around physician-supervised clinical delivery, which means the staffing architecture is fundamentally different from retail or food-service franchises. Treatment sessions are designed to run between 30 and 90 minutes with same-day discharge, enabling relatively high patient throughput for a clinical environment without the overnight or extended-stay complexity of hospital-adjacent businesses. Franchisees are expected to lead a team of diverse healthcare professionals, including the clinical staff delivering regenerative injections, primary care consultations, and telemedicine services. The model accommodates multiple entry pathways: an investor can open a new clinic from scratch under either an investor model or a medical professional model, an existing medical practice can convert to the NexGenEsis system, or a current healthcare operator can add regenerative treatments as a service extension to an existing clinical operation. Each of these pathways carries different build-out costs and timelines, which explains much of the spread within the $168,250 to $361,495 total investment range. The training program encompasses NexGenEsis University curriculum alongside hands-on clinical instruction, covering equipment operation, product knowledge, patient scheduling and billing, customer service standards, and sales and marketing strategies for a cash-pay patient acquisition environment. Training costs range from $1,500 to $10,000 for the standard curriculum, with an additional medical training component priced up to $4,495. The corporate support structure includes assistance with business planning, employee recruitment, and compliance with healthcare regulations and safety standards — operational dimensions that are particularly complex in a medical franchise and where experienced guidance meaningfully de-risks the franchisee's early operating period. Each franchisee is granted exclusive territory rights covering a population of between 175,000 and 200,000 residents, and NexGenEsis commits to not establishing competing franchise locations within that designated area, though the company retains rights to operate corporate locations and multi-area marketing programs outside the protected zone. A 12-month patient follow-up program, with scheduled appointments at the six-month and twelve-month marks, is built into the clinical protocol, providing a structured patient retention mechanism that supports recurring revenue.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document, which means prospective franchisees cannot rely on franchisor-provided average revenue or profit figures as part of their official due diligence process. However, third-party research and industry data sources have surfaced revenue figures that, if accurate, paint a compelling picture of unit-level economics. Some sources report an average unit volume of $747,000, while others cite an average gross revenue figure of $959,704 per location. If the $959,704 figure is accurate, it represents a substantial premium over the alternative medicine sub-sector average of $317,965 in reported gross revenue — a variance of more than 200% that, if verified through franchisee validation calls, would represent an extraordinary unit economics profile for the initial investment range. The cash-pay nature of the business model is a double-edged dynamic that sophisticated investors must evaluate carefully. Because insurance typically does not reimburse regenerative therapies such as platelet-rich plasma, alpha 2 macroglobulin, or bone marrow aspirate injections, the practice operates in an out-of-pocket patient environment where marketing effectiveness directly determines patient volume and, consequently, revenue. This creates a model where strong operators who invest in local marketing can generate premium revenue, but where underinvested or poorly marketed locations may struggle to fill appointment capacity. Applying the 7% royalty rate to the cited $959,704 gross revenue figure produces an annual royalty obligation of approximately $67,179, and adding the 1% brand fund contribution yields a combined ongoing fee of roughly $76,776 per year at that revenue level. Prospective franchisees should conduct thorough franchisee validation interviews — speaking directly with current NexGenEsis operators about actual revenue ranges, patient acquisition costs, and time to breakeven — before committing capital, given the absence of Item 19 disclosure.

The NexGen Franchising, LLC NexGenEsis Healthcare system has demonstrated measurable unit growth since entering the franchise channel between 2020 and 2022. The current footprint of 12 total U.S. locations, with reports of 24 franchise units awarded in total history and 17 franchise units awarded within the most recent 12-month period, indicates that franchisor sales activity is significantly outpacing open location count — a common feature of emerging franchise systems where franchise award velocity runs ahead of the pace at which new locations complete build-out and reach opening day. The geographic concentration in the Sun Belt, specifically Texas and Arizona, reflects a deliberate population-density and climate-compatible market strategy, as warmer-climate markets tend to support higher concentrations of active adults and retirees who are the primary demographic for regenerative pain management services. Additional markets in Hawaii, Louisiana, Mississippi, and Pennsylvania demonstrate that the brand is not limiting itself to a single regional identity and is actively pursuing a national footprint. The company's stated mission to bring world-class medical care to every corner of the country positions NexGenEsis as an expansion-stage brand with both corporate resources and franchise development infrastructure deployed toward nationwide scale. The adoption of telemedicine within the service menu is a meaningful competitive differentiator, allowing NexGenEsis clinics to serve patients across broader geographic areas and creating a recurring touchpoint with the patient population between in-person regenerative treatment appointments. The early-mover advantage in the franchise channel for regenerative medicine is a real and time-limited competitive moat: as the broader industry grows at 16% to 24% annually, the number of competing franchise systems entering the space will increase, and brands that have established territorial presence, brand recognition, and clinical reputation in key markets before that competition arrives will retain a structural advantage that later entrants simply cannot replicate.

The ideal NexGen Franchising, LLC NexGenEsis Healthcare franchisee is an individual with the management capability to lead a team of diverse healthcare professionals, the business acumen to operate in a cash-pay environment that requires proactive local marketing, and either a clinical background or the organizational confidence to hire and retain qualified medical staff. The company explicitly offers two distinct entry models — an investor model and a medical professional model — acknowledging that the franchise opportunity is designed to be accessible both to licensed clinicians who want to operate their own practice under a proven system and to business operators who bring capital and management experience without a direct clinical background. The availability of a conversion pathway for existing medical practices also suggests that established primary care physicians, physical therapists, or urgent care operators who want to expand their service menu into the regenerative space represent a natural candidate profile. Territory availability spans multiple U.S. regions, with the Sun Belt markets of Texas and Arizona being notably active, alongside opportunities in Hawaii, Louisiana, Mississippi, and Pennsylvania. The company currently operates exclusively within the United States and has no announced plans for international expansion, meaning all franchise development activity and support infrastructure is concentrated on domestic market penetration. One notable early-franchisee incentive is direct CEO access: NexGenEsis has communicated that the next 10 new franchisees will have direct contact with Dr. Lawrence Bourgeois, a level of executive engagement that is unusual in franchising and reflects the system's early-stage character. Prospective investors should understand that franchise agreement terms, renewal rights, and transfer conditions should be carefully reviewed with a qualified franchise attorney, as these terms govern the franchisee's long-term relationship with the brand and the conditions under which they can eventually sell their investment.

For investors conducting serious due diligence on healthcare franchise opportunities, the NexGen Franchising, LLC NexGenEsis Healthcare franchise opportunity presents a genuinely differentiated thesis: an early-stage system operating in a $29 billion alternative healthcare market growing at 16% or more annually, with reported per-unit gross revenues that substantially exceed the category average, a clinically credentialed founding and executive team, and a product mix anchored to demographic trends that are structurally accelerating over the next decade. The NexGen Franchising, LLC NexGenEsis Healthcare franchise investment range of $168,250 to $361,495 is accessible relative to many healthcare franchise concepts, and the veteran discount on the $55,000 franchise fee makes the entry point even more competitive for qualified military candidates. The primary risks an investor must assess independently include the limited number of currently open franchise locations from which to validate real-world unit economics, the cash-pay patient acquisition challenge inherent to regenerative medicine services, and the developing brand recognition relative to more established healthcare franchise systems. The NexGen Franchising, LLC NexGenEsis Healthcare franchise fee of $55,000 and 7% royalty structure must be evaluated against validated revenue data gathered through direct franchisee interviews, not solely through franchisor-provided estimates. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark NexGenEsis against competing healthcare and regenerative medicine franchise opportunities across every relevant financial and operational dimension. Explore the complete NexGen Franchising, LLC NexGenEsis Healthcare franchise profile on PeerSense to access the full suite of independent franchise intelligence data.